Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1101-1120 of 1,307 trials

Hypochondroplasia: Infigratinib for Growth

We are investigating whether infigratinib can help children aged 3 to 11 with hypochondroplasia grow taller and improve their overall health. The study will also look at the safety of this new treatment.

Hypochondroplasia>2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicinePediatrics

Baricitinib for Children Hospitalized with COVID-19

We are studying how the medication baricitinib works in children aged 1 to under 18 years who are hospitalized with COVID-19. This research aims to ensure the safety and proper dosing for young patients.

COVID-19≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPulmonology

Triple-Negative Breast Cancer: Sacituzumab Tirumotecan Study

We are studying a new treatment for people with previously untreated triple-negative breast cancer. This trial compares a new drug alone and with another medication against standard treatment to see which works better.

Triple Negative Breast Cancer (TNBC)>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementGynecology and ObstetricsOncology

Recurrent Ovarian Cancer: Olaparib vs. Chemotherapy

We are studying whether olaparib can help patients with recurrent ovarian cancer live longer without disease progression after surgery, compared to standard chemotherapy. The trial also looks at safety and quality of life.

Recurrent Ovarian CancerConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Patent Ductus Arteriosus: Paracetamol Treatment in Premature Infants

We are studying whether early treatment with Paracetamol helps extremely low birth weight infants with Patent Ductus Arteriosus avoid serious complications. This trial compares the effects of Paracetamol to a placebo.

Patent Ductus Arteriosus≤3 monthsConfirmation phase (III)Investigational MedicinesCardiologyPediatrics

Transfer Factor TFI for Recurrent Infections

We are testing a new treatment for people with frequent respiratory or urinary tract infections and recurrent herpes. The study aims to see if it can help reduce the number of new infections.

Recurrent Respiratory Tract InfectionsRecurrent Urinary Tract Infections6-12 monthsConfirmation phase (III)Infectious DiseasesPulmonologyUrology

Rheumatoid Arthritis: Spironolactone Study

We are investigating whether spironolactone can help reduce symptoms in people with active rheumatoid arthritis. The study will also monitor safety and other health indicators.

Rheumatoid Arthritis>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineRheumatology

Allergic Rhinitis: Beltavac® Immunotherapy

We are studying the effectiveness and safety of Beltavac®, a new immunotherapy, for people with allergic rhinitis caused by house dust mites. The trial will also look at how it affects allergy symptoms and overall quality of life.

House Dust Mite Allergy>2 yearsConfirmation phase (III)Investigational MedicinesAllergologyOphthalmologyOtolaryngology

Diffuse Large B-Cell Lymphoma: Polatuzumab Vedotin with R-CHP

We are studying whether a new treatment combining polatuzumab vedotin with standard chemotherapy helps patients with diffuse large B-cell lymphoma live longer without disease progression compared to the current standard treatment.

Diffuse Large B-Cell Lymphoma>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesOncology

SAPHO Syndrome: Etanercept Treatment Study

We are testing the safety and effectiveness of etanercept in patients with SAPHO syndrome who are already on standard treatments. This study aims to explore new treatment options for better management of their condition.

SAPHO Syndrome6-12 monthsEfficacy phase (II)Confirmation phase (III)Standard MedicinesInfectious DiseasesRheumatology

Neovascular Age-Related Macular Degeneration: Port Delivery System with Ranibizumab

We are studying a new delivery system for ranibizumab in patients with neovascular age-related macular degeneration. The goal is to see how well it works and how it affects patients' treatment experiences.

Neovascular Age-Related Macular Degeneration1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOphthalmology

Delayed Sleep-Wake Phase Disorder: Tasimelteon Study

We are investigating whether tasimelteon can help people with Delayed Sleep-Wake Phase Disorder fall asleep faster and improve their overall sleep quality compared to a placebo.

Delayed Sleep-Wake Phase Disorder≤3 monthsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteNeurologyPsychiatry

HER2-Expressing Ovarian Cancer: Trastuzumab Deruxtecan with Bevacizumab

We are studying a new combination treatment for patients with HER2-expressing ovarian cancer to see if it works better than standard therapy. The trial will assess safety and how well the treatments help manage the disease.

Ovarian Cancer>2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Systemic Sclerosis: Nintedanib and Tocilizumab Study

We are testing a combination of nintedanib and tocilizumab for patients with systemic sclerosis and interstitial lung disease. The goal is to see if this new treatment is more effective than standard therapies.

Systemic SclerosisSystemic Sclerosis with Interstitial Lung Disease1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPulmonologyRheumatology

CIDP: Riliprubart Treatment Study

We are studying the long-term safety and effectiveness of riliprubart for individuals with chronic inflammatory demyelinating polyneuropathy. This trial will help us understand how well it works in improving disability and strength.

Chronic Inflammatory Demyelinating Polyneuropathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNeurology

Cutaneous Melanoma: IMA203 Treatment Study

We are comparing a new treatment called IMA203 with the best available options for patients with advanced skin cancer. This study aims to see if IMA203 is more effective and safe for those who have already been treated.

Skin Melanoma1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Alzheimer's Disease: Tau and Amyloid Brain Imaging Study

We are investigating how tau protein deposits in the brain can help distinguish between Alzheimer's disease and other conditions. This study may provide insights into early diagnosis and disease progression.

Alzheimer's Disease>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteNeurology

Multiple Myeloma: Fluciclovine PET/CT Imaging Study

We are investigating a new imaging method for multiple myeloma patients to see how it compares to standard imaging. This study aims to understand its effectiveness and safety in detecting the disease.

Multiple MyelomaEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncologyOtolaryngology

ELGN-2112 for Intestinal Malabsorption in Preterm Infants

We are studying whether ELGN-2112 can help preterm infants with intestinal malabsorption achieve full feeding sooner and reduce the risk of serious complications. This trial compares the new treatment to a placebo to assess its safety and effectiveness.

Intestinal Malabsorption>2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Menstrual Migraine: Rimegepant Study

We are investigating whether Rimegepant can help prevent menstrual migraines in women aged 18 to 45. This study compares its effects to a placebo to see if it reduces migraine frequency and improves quality of life.

Menstrual Migraine6-12 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesGynecology and ObstetricsNeurology